Clinical and molecular determinants of bleeding-related adverse outcomes in high-grade glioma

ConclusionIn this study we found that the use of rivaroxaban was associated with more bleeding-related events compared to apixaban and enoxaparin in patients with high-grade glioma. In this study we also found that the diagnosis of astrocytoma, IDH mutant, grade 4 was associated with more bleeding events. However, this is based on a small study and there is a need for larger studies to further evaluate these results.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research